J 2022

Lung Cancer Versus "Young Cancer": Is Non-Small Cell Lung Cancer in Young Patients a Different Entity?

BRATOVÁ, Monika, Kristián BRAT, Karolina HURDALKOVA, Magda BARINOVA, Marie DROSSLEROVA et. al.

Základní údaje

Originální název

Lung Cancer Versus "Young Cancer": Is Non-Small Cell Lung Cancer in Young Patients a Different Entity?

Autoři

BRATOVÁ, Monika (203 Česká republika, domácí), Kristián BRAT (703 Slovensko, garant, domácí), Karolina HURDALKOVA (203 Česká republika), Magda BARINOVA (203 Česká republika), Marie DROSSLEROVA (203 Česká republika), Juraj KULTAN, Matyas WANKE (203 Česká republika), Leona KOUBKOVA (203 Česká republika), Jana KREJCI (203 Česká republika) a Martin SVATON (203 Česká republika)

Vydání

JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, NEW ROCHELLE, MARY ANN LIEBERT, INC, 2022, 2156-5333

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.000

Kód RIV

RIV/00216224:14110/22:00125388

Organizační jednotka

Lékařská fakulta

UT WoS

000715838900001

Klíčová slova anglicky

non-small cell lung cancer; young patients; younger than the age of 40 years; overall survival; prognosis; mutations

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 24. 2. 2023 09:52, Mgr. Tereza Miškechová

Anotace

V originále

Purpose: Aim was to analyze demographic and tumor characteristics, treatment, and survival of patients with lung cancer younger than 40 years of age (U40) compared to older subgroups (41-70 and >70 years).

Methods: We analyzed data of young patients diagnosed and treated in 2011-2019 in five pneumo-oncology centers in Czechia. Standard descriptive statistics, chi-squared test, Fisher exact test, and Kaplan-Meier survival analysis were used. p-Values <0.05 were considered significant. These data were compared with two control subgroups (cohort 1: 41-70 years, cohort 2: >70 years).

Results: We identified 66 patients U40, 61 with non-small cell lung cancer (NSCLC)-50.8% men, mean age 34.6 years, 54.1% nonsmokers, daily good performance status, and 82% in stage IV. Adenocarcinomas dominated, endothelial growth factor receptor (EGFR) positivity was less common than in older groups contrary to anaplastic lymphoma kinase (ALK) mutations. Median progression-free survival was 3.7 months (vs. 4.9 and 6.2 months; p = 0.006) and overall survival reached 11.7 months (vs. 22.3 and 27.3 months; p < 0.001). Young patients in stage IV and never-smokers had shorter survival than older patients.

Conclusion: Patients with NSCLC U40 had significantly worse prognosis than older patients.